Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 3, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The filing details a specific transaction on April 25, 2006, where 93 Ordinary shares were sold on behalf of a participant in the SmithKline Beecham Unapproved Matching Plan. The sale price was GBP 14.89 per share. This transaction was executed by the Administrators of the SmithKline Beecham Employee Benefit Trust.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that Mr. J Heslop, a Company director, is interested in the shares held in the fund in the same capacity as other non-US employees or former employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the 93-share sale.
- Confirm the current status of the SmithKline Beecham Unapproved Matching Plan and its alignment with current company policies.
- Review the full disclosure history for Director J Heslop to understand the scope of his interest in the Trust.